MA38540B1 - Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 - Google Patents
Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6Info
- Publication number
- MA38540B1 MA38540B1 MA38540A MA38540A MA38540B1 MA 38540 B1 MA38540 B1 MA 38540B1 MA 38540 A MA38540 A MA 38540A MA 38540 A MA38540 A MA 38540A MA 38540 B1 MA38540 B1 MA 38540B1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- alpha
- derivatives useful
- integrin antagonists
- naphthyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention porte sur un composé de formule (i) ou un sel de celle-ci (i), dans laquelle r1 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle, r2 représente un atome d'hydrogène ou un atome de fluor et r3 représente un atome d'hydrogène, un groupe méthyle ou un groupe éthyle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1305668.4A GB201305668D0 (en) | 2013-03-28 | 2013-03-28 | Avs6 Integrin Antagonists |
| PCT/EP2014/056013 WO2014154725A1 (fr) | 2013-03-28 | 2014-03-26 | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38540A1 MA38540A1 (fr) | 2017-02-28 |
| MA38540B1 true MA38540B1 (fr) | 2017-10-31 |
Family
ID=48444909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38540A MA38540B1 (fr) | 2013-03-28 | 2014-03-26 | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US10023568B2 (fr) |
| EP (2) | EP2989100B1 (fr) |
| JP (1) | JP6095847B2 (fr) |
| KR (2) | KR101775085B1 (fr) |
| CN (1) | CN105189499B (fr) |
| AR (1) | AR095768A1 (fr) |
| AU (1) | AU2014243068C1 (fr) |
| BR (1) | BR112015024530A8 (fr) |
| CA (1) | CA2903358A1 (fr) |
| CL (1) | CL2015002860A1 (fr) |
| CR (1) | CR20150509A (fr) |
| CY (1) | CY1120188T1 (fr) |
| DK (1) | DK2989100T3 (fr) |
| DO (1) | DOP2015000251A (fr) |
| EA (1) | EA027305B1 (fr) |
| ES (1) | ES2665597T3 (fr) |
| GB (1) | GB201305668D0 (fr) |
| HK (1) | HK1214262A1 (fr) |
| HR (1) | HRP20180528T1 (fr) |
| HU (1) | HUE036750T2 (fr) |
| IL (1) | IL241184A0 (fr) |
| LT (1) | LT2989100T (fr) |
| MA (1) | MA38540B1 (fr) |
| ME (1) | ME02987B (fr) |
| MX (1) | MX363288B (fr) |
| NO (1) | NO2989100T3 (fr) |
| NZ (1) | NZ629025A (fr) |
| PE (1) | PE20151606A1 (fr) |
| PH (1) | PH12015502232B1 (fr) |
| PL (1) | PL2989100T3 (fr) |
| PT (1) | PT2989100T (fr) |
| RS (1) | RS57220B1 (fr) |
| SG (1) | SG11201506813QA (fr) |
| SI (1) | SI2989100T1 (fr) |
| TW (1) | TWI632143B (fr) |
| UA (1) | UA114952C2 (fr) |
| UY (1) | UY35505A (fr) |
| WO (1) | WO2014154725A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3929196T (lt) | 2013-09-24 | 2023-09-25 | Fujifilm Corporation | Farmacinė kompozicija junginio, kurio sudėtyje yra azotas arba jo druska, arba jo metalo kompleksas |
| GB201417018D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN107428828A (zh) | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| GB201615588D0 (en) | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
| GB201604589D0 (en) * | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) * | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| SI3538525T1 (sl) | 2016-11-08 | 2022-09-30 | Bristol-Myers Squibb Company | 3-substituirane propionske kisline kot inhibitorji alfa v integrina |
| RS61453B1 (sr) * | 2016-11-08 | 2021-03-31 | Bristol Myers Squibb Co | Amidi pirola kao inhibitori alfa v integrina |
| MX2019005306A (es) | 2016-11-08 | 2019-08-12 | Squibb Bristol Myers Co | Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v. |
| CN110214137A (zh) | 2016-11-08 | 2019-09-06 | 百时美施贵宝公司 | 作为αv整联蛋白拮抗剂的吲唑衍生物 |
| JP7128811B2 (ja) | 2016-11-08 | 2022-08-31 | ブリストル－マイヤーズ スクイブ カンパニー | アルファｖインテグリン阻害剤としてのアゾールアミドおよびアミン |
| EP3558303A4 (fr) * | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | Composés acides aminés et leurs procédés d'utilisation |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| RU2022108080A (ru) | 2017-02-28 | 2022-04-07 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
| US11292802B2 (en) | 2017-11-07 | 2022-04-05 | Bristol-Myers Squibb Company | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors |
| SG11202008609UA (en) | 2018-03-07 | 2020-10-29 | Pliant Therapeutics Inc | Amino acid compounds and methods of use |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| EP3843728A4 (fr) * | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | Inhibiteurs de l'intégrine (alpha-v)(bêta -6) |
| EP3843727A4 (fr) * | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | Inhibiteurs de l'intégrine (alpha-v)(bêta-6) |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022183360A1 (fr) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Peptides synthétiques courts et leurs utilisations pour le traitement de la sécheresse oculaire |
| WO2024129931A1 (fr) * | 2022-12-14 | 2024-06-20 | Alnylam Pharmaceuticals, Inc. | LIGANDS DE L'INTÉGRINE ALPHA-V BÊTA-6 (ανβ6) POUR UNE DISTRIBUTION EXTRA-HÉPATIQUE |
| WO2024145245A2 (fr) * | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Inhibiteurs de l'intégrine alpha-v-bêta-8 et leurs utilisations |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| EP1047425A4 (fr) * | 1997-12-17 | 2009-04-22 | Merck & Co Inc | Antagonistes du recepteur de l'integrine |
| BR9813769A (pt) | 1997-12-17 | 2000-10-10 | Merck & Co Inc | Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste. |
| PT1187592E (pt) | 1999-06-02 | 2007-10-19 | Merck & Co Inc | Antagonistas dos receptores de integrina alfa v |
| JP2003502373A (ja) * | 1999-06-23 | 2003-01-21 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
| WO2001024797A1 (fr) | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Antagonistes des recepteurs d'integrine |
| PL355011A1 (en) * | 1999-11-08 | 2004-03-22 | Merck & Co, Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| US7056909B2 (en) | 2000-07-26 | 2006-06-06 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| AU2001290772A1 (en) | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002053099A2 (fr) | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methodes et compositions de traitement d'une parodontopathie |
| DE10112771A1 (de) * | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| EP2287198A3 (fr) | 2002-03-13 | 2011-05-25 | Biogen Idec MA Inc. | Anticorps anti-alpha V bêta 6 |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP1592421A1 (fr) | 2002-12-20 | 2005-11-09 | Pharmacia Corporation | Acides heterocycliques comme antagonistes du recepteur d'integrin |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| JP4641526B2 (ja) | 2003-11-03 | 2011-03-02 | グラクソ グループ リミテッド | 流体分配デバイス |
| WO2008118455A1 (fr) | 2007-03-23 | 2008-10-02 | Amgen Inc. | Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k) |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| EP2211615A4 (fr) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase |
| WO2011111880A1 (fr) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3 |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112017017888A2 (pt) | 2015-02-19 | 2018-04-10 | Scifluor Life Sciences Inc | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes |
| EP3268369A4 (fr) | 2015-03-10 | 2018-08-08 | The Regents of The University of California | Inhibiteurs anti-intégrine alphavbeta1 et méthodes d'utilisation associées |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2013
- 2013-03-28 GB GBGB1305668.4A patent/GB201305668D0/en not_active Ceased
-
2014
- 2014-03-26 MA MA38540A patent/MA38540B1/fr unknown
- 2014-03-26 RS RS20180537A patent/RS57220B1/sr unknown
- 2014-03-26 NO NO14712666A patent/NO2989100T3/no unknown
- 2014-03-26 BR BR112015024530A patent/BR112015024530A8/pt not_active IP Right Cessation
- 2014-03-26 PL PL14712666T patent/PL2989100T3/pl unknown
- 2014-03-26 TW TW103111317A patent/TWI632143B/zh not_active IP Right Cessation
- 2014-03-26 KR KR1020157031064A patent/KR101775085B1/ko active IP Right Grant
- 2014-03-26 NZ NZ629025A patent/NZ629025A/en not_active IP Right Cessation
- 2014-03-26 ME MEP-2018-83A patent/ME02987B/fr unknown
- 2014-03-26 EP EP14712666.8A patent/EP2989100B1/fr active Active
- 2014-03-26 SG SG11201506813QA patent/SG11201506813QA/en unknown
- 2014-03-26 ES ES14712666.8T patent/ES2665597T3/es active Active
- 2014-03-26 EA EA201591503A patent/EA027305B1/ru not_active IP Right Cessation
- 2014-03-26 CN CN201480018839.6A patent/CN105189499B/zh not_active Expired - Fee Related
- 2014-03-26 DK DK14712666.8T patent/DK2989100T3/en active
- 2014-03-26 UA UAA201508518A patent/UA114952C2/uk unknown
- 2014-03-26 UY UY0001035505A patent/UY35505A/es not_active Application Discontinuation
- 2014-03-26 HU HUE14712666A patent/HUE036750T2/hu unknown
- 2014-03-26 EP EP18157255.3A patent/EP3360876A1/fr not_active Withdrawn
- 2014-03-26 AU AU2014243068A patent/AU2014243068C1/en not_active Ceased
- 2014-03-26 KR KR1020177024389A patent/KR102042141B1/ko active IP Right Grant
- 2014-03-26 PE PE2015002064A patent/PE20151606A1/es active IP Right Grant
- 2014-03-26 SI SI201430687T patent/SI2989100T1/en unknown
- 2014-03-26 PT PT147126668T patent/PT2989100T/pt unknown
- 2014-03-26 WO PCT/EP2014/056013 patent/WO2014154725A1/fr active Application Filing
- 2014-03-26 MX MX2015013742A patent/MX363288B/es unknown
- 2014-03-26 AR ARP140101378A patent/AR095768A1/es unknown
- 2014-03-26 US US14/778,095 patent/US10023568B2/en not_active Expired - Fee Related
- 2014-03-26 LT LTEP14712666.8T patent/LT2989100T/lt unknown
- 2014-03-26 CA CA2903358A patent/CA2903358A1/fr not_active Abandoned
- 2014-03-26 JP JP2016504647A patent/JP6095847B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-06 IL IL241184A patent/IL241184A0/en active IP Right Grant
- 2015-09-24 PH PH12015502232A patent/PH12015502232B1/en unknown
- 2015-09-25 CL CL2015002860A patent/CL2015002860A1/es unknown
- 2015-09-28 DO DO2015000251A patent/DOP2015000251A/es unknown
- 2015-09-28 CR CR20150509A patent/CR20150509A/es unknown
-
2016
- 2016-03-02 HK HK16102407.5A patent/HK1214262A1/zh not_active IP Right Cessation
-
2018
- 2018-03-29 HR HRP20180528TT patent/HRP20180528T1/hr unknown
- 2018-05-09 CY CY20181100479T patent/CY1120188T1/el unknown
- 2018-06-13 US US16/007,584 patent/US10450312B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38540B1 (fr) | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
| MA35172B1 (fr) | Melanges pestticides contenant des derives d'isoxazoline | |
| RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
| MY177250A (en) | Novel nicotinamide derivative or salt thereof | |
| MY156669A (en) | Pesticidal composition and its use | |
| EA201491936A1 (ru) | Азотсодержащее гетероциклическое соединение | |
| MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
| MA38404A1 (fr) | Nouveaux dérivés de pyridine | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| BR112012027378A2 (pt) | composto pesticida e seu uso | |
| BR112018004447A2 (pt) | derivado de biarila e medicamento contendo o mesmo | |
| BR112013015604A2 (pt) | novo derivado de isoquinolina substituído | |
| MA39305A3 (fr) | Dérivés d'éthynyle | |
| FR3020809B1 (fr) | Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique | |
| MA38010B1 (fr) | Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 | |
| MA20150280A2 (fr) | Dérivés d'aryléthynyle | |
| MX358151B (es) | Derivado de sitaxentan. | |
| RS53032B (en) | DIHIDRO-OXAZOLOBENZODIAZEPINONE DERIVATIVES, PROCEDURES FOR THEIR PRODUCTION AND THE PHARMACEUTICAL MIXTURES CONTAINING THESE COMPOUNDS | |
| BR112016029347A2 (pt) | ?repelente de animal roedor, e, método para repelir um animal roedor? | |
| EA201400269A1 (ru) | Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина |